Virus-like particle vaccines and adjuvants: The HPV paradigm

Expert Review of Vaccines

Volumn 8, Issue 10, 2009, Pages 1379-1398

  Buonaguro, Franco Maria ^a   Tornesello, Maria Lina ^a   Buonaguro, Luigi ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant; HPV vaccine; Th1 th2 polarization; Virus like particle

Indexed keywords

AGATOLIMOD; ALUMINUM SALT; CALCIUM SALT; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; DOXORUBICIN; FREUND ADJUVANT; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; MONTANIDE ISA 51; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; PLACEBO; PROTEIN VP2; PROTEIN VP5; QS 21; QUIL A; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SILGARD; TOLL LIKE RECEPTOR AGONIST; TOMATINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGENICITY; CELL POLARITY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FELINE PANLEUKOPENIA VIRUS; GRANULOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INNATE IMMUNITY; MEMORY CELL; MYALGIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

EID: 70349900710     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.81     Document Type: Review

References (217)

1. Petry H, Goldmann C, Ast O, Luke W. The use of virus-like particles for gene transfer. Curr. Opin Mol. Ther. 5(5), 524-528 (2003).
2. Crawford LV, Crawford EM, Watson DH. The physical characteristics of polyoma virus. I. Two types of particle. Virology 18, 170-176 (1962).
3. Michel MR, Hirt B, Weil R. Mouse cellular DNA enclosed in polyoma viral capsids (pseudovirions). Proc. Natl Acad. Sci. USA 58(4), 1381-1388 (1967).
4. Winocour E. Purification of polyoma virus. Virology 19, 158-168 (1963).
5. Winocour E. Further studies on the incorporation of cell DNA into polyoma-related particles. Virology 34(4), 571-582 (1968).
6. Brady JN, Consigli RA. Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein. J. Virol. 27(2), 436-442 (1978).
7. Salunke DM, Caspar DL, Garcea RL. Self-assembly of purified polyomavirus capsid protein VP1. Cell 46(6), 895-904 (1986).
8. Montross L, Watkins S, Moreland RB, Mamon H, Caspar DL, Garcea RL. Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VPl. J. Virol. 65(9), 4991-4998 (1991).
9. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus like particles. J. Virol. 67(4), 1936-1944 (1993).
10. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185(1), 251-257 (1991).
11. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89(24), 12180-12184 (1992). •• Description of the high immunogenicity of human papillomavirus (HPV)-16 L1-based virus-like particles (VLPs).
12. Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N, Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J. Virol. 59(1), 176-180 (1986). (Pubitemid 16062513)
13. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59(1), 103-112 (1989). (Pubitemid 19248562)
14. Delchambre M, Gheysen D, Thines D et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J. 8(9), 2653-2660 (1989). (Pubitemid 19273350)
15. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol. 64(12), 5695-5700 (1990).
16. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst. 93(4), 284-292 (2001).
17. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008).
18. + dendritic cells capable of inducing antiviral T cell responses. J. Immunol. 182(7), 4200-4207 (2009). •• Description of dermal dendritic cells (DCs) and their role in antigen presentation after natural infection.
19. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108(3), 415-423 (2001).
20. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16(3), 273-282 (2000).
21. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA 100(11), 6753-6758 (2003).
22. Schirmbeck R, Bohm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39(1-2), 111-119 (1996). (Pubitemid 26390702)
23. Goldmann C, Stolte N, Nisslein T, Hunsmann G, Luke W, Petry H. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J. Virol. Methods 90(1), 85-90 (2000). (Pubitemid 30697051)
24. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172(3), 1777-1785 (2004). •• Description of adjuvant role of CpGs loaded in VLPs in the absence of systemic side effects. (Pubitemid 38116826)
25. Sasagawa T, Pushko P, Steers G et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206(1), 126-135 (1995).
26. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73(11), 9063-9071 (1999). (Pubitemid 29487059)
27. Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18(11-12), 1051-1058 (2000).
28. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21), 1645-1651 (2002).
29. Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183(10), 1485-1493 (2001).
30. Lopez de Turiso JA, Cortes E, Martinez C et al. Recombinant vaccine for canine parvovirus in dogs. J. Virol. 66(5), 2748-2753 (1992).
31. Martinez C, Dalsgaard K, Lopez de Turiso JA, Cones E, Vela C, Casal JI. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 10(10), 684-690 (1992).
32. Maranga L, Rueda P, Antonis AF et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl. Microbiol. Biotechnol. 59(1), 45-50 (2002).
33. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72(2), 1345-1353 (1998).
34. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75(20), 9713-9722 (2001).
35. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 117(1), 40-48 (1999).
36. Goldmann C, Petry H, Frye S etal. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J. Virol. 73(5), 4465-4469 (1999).
37. Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 192(2), 512-524 (1993).
38. Kibenge FS, Qian B, Nagy E, Cleghorn JR, Wadowska D. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can. J. Vet. Res. 63(1), 49-55 (1999).
39. French TJ, Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J. Virol. 64(4), 1530-1536 (1990). (Pubitemid 20104888)
40. Roy P, Boyce M, Noad R. Prospects for improved bluetongue vaccines. Nat. Rev. Microbiol. 7(2), 120-128 (2009).
41. Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res. 21(5), 1219-1223 (1993). (Pubitemid 23155619)
42. Roy P, French T, Erasmus BJ. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10(1), 28-32 (1992).
43. Roy P, Bishop DH, LeBlois H, Erasmus BJ. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12(9), 805-811 (1994). (Pubitemid 24190561)
44. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64(5), 1998-2003 (1990).
45. Veronesi E, Hamblin C, Mellor PS. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23(48-49), 5509-5516 (2005). (Pubitemid 41608599)
46. Betenbaugh M, Yu M, Kuehl K et al. Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res. 38(2-3), 111-124(1995).
47. Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 214(1), 50-58 (1995).
48. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72(5), 3827-3836 (1998). (Pubitemid 28188682)
49. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75(13), 6154-6165 (2001). (Pubitemid 32553146)
50. Yao Q, Kuhlmann FM, Eller R, Compans RW, Chen C. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res. Hum. Retroviruses 16(3), 227-236 (2000).
51. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34(2), 417-423 (2001). (Pubitemid 32702356)
52. Wagner R, Deml L, Notka F et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 39(1-2), 93-103 (1996). (Pubitemid 26390700)
53. Yao Q, Vuong V, Li M, Compans RW. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 20(19-20), 2537-2545 (2002). (Pubitemid 34615593)
54. Buonaguro L, Buonaguro FM, Tornesello ML et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 49(1), 35-47 (2001). (Pubitemid 32146577)
55. Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM. Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. J. Virol. 83(1), 304-313 (2009).
56. Buonaguro L, Devito C, Tornesello ML et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25(32), 5968-5977 (2007). (Pubitemid 47082465)
57. Nieba L, Bachmann MF. A new generation of vaccines. Mod. Asp. Immunobiol. 1, 36-39 (2000).
58. Bachmann MF, Jennings GT. Virus-like particles: combining innate and adaptive immunity for effective vaccination. In: Novel Vaccination Strategies. Kaufmann SHE (Ed.). Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim, Germany, 415-432 (2004).
59. + dendritic cells: a dispensable role for TAP. Eur. J. Immunol. 32(3), 818-825 (2002).
60. Woo WP, Doan T, Herd KA, Netter HJ, Tindle RW Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J. Virol. 80(8), 3975-3984 (2006).
61. Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J. Virol. 79(2), 717-724 (2005). (Pubitemid 40053854)
62. Ionescu RM, Przysiecki CT, Liang X et al. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J. Pharm. Sci. 95(1), 70-79 (2006).
63. Kang SM, Yao Q, Guo L, Compans RW. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J. Virol. 77(18), 9823-9830 (2003). (Pubitemid 37122063)
64. Neurath AR, Strick N, Girard M. Hepatitis B virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail. Mol. Immunol. 26(1), 53-62 (1989).
65. Schwarz K, Meijerink E, Speiser DE et al. Efficient homologous prime - boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immunol. 35(3), 816-821 (2005).
66. Brown WL, Mastico RA, Wu M et al. RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45(4-6), 371-380 (2002). (Pubitemid 36173447)
67. Peacey M, Wilson S, Baird MA, Ward VK. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnol. Bioeng. 98(5), 968-977 (2007).
68. Laurent S, Vautherot JF, Madelaine MF, Le Gall G, Rasschaert D. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol. 68(10), 6794-6798 (1994). (Pubitemid 24294936)
69. Beyer T, Herrmann M, Reiser C, Bertling W, Hess J. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr. Drug Targets Infect. Disord. 1(3), 287-302 (2001).
70. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl Acad. Sci. USA 94(14), 7503-7508 (1997).
71. Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur. J. Immunol. 28(4), 1401-1407 (1998).
72. Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20(17-18), 2287-2295 (2002). (Pubitemid 34497039)
73. Okitsu SL, Silvie O, Westerfeld N et al. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a Phase 1a clinical trial. PLoS ONE 2(12), e1278 (2007). (Pubitemid 351722474)
74. Hunziker IP, Zurbriggen R, Glueck R et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38(6), 475-484 (2001).
75. Cho JE, Kim HS, Ahn WS, Park YS. Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins. J. Microencapsul. 18(4), 421-431 (2001).
76. Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 20(Suppl. 5), B10-B16 (2002). (Pubitemid 35435391)
77. Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14(10), 982-986 (1996). (Pubitemid 26271071)
78. Gluck U, Gebbers JO, Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73(9), 7780-7786 (1999). (Pubitemid 29383262)
79. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344(8916), 160-163 (1994). (Pubitemid 24218879)
80. Cusi MG, Zurbriggen R, Valassina M et al. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology 277(1), 111-118 (2000). (Pubitemid 30951091)
81. Waelti E, Wegmann N, Schweninger R et al. Targeting Her-2/Neu with antirat Neu virosomes for cancer therapy. Cancer Res. 62(2), 437-444 (2002). (Pubitemid 34106416)
82. Krishnan A, Verma SK, Mani P, Gupta R, Kundu S, Sarkar DP. A histidine switch in hemagglutinin-neuraminidase triggers paramyxovirus-cell membrane fusion. J. Virol. 83(4), 1727-1741 (2009).
83. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65(2), 623-629 (1997).
84. Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique. Bull. Soc Centr. Med. Vet. 101, 227-234 (1925).
85. Ramon G. Procedres pour acroitre la production des antitoxines. Ann. Inst. Pasteur (Paris) 40, 1-10(1926).
86. Glenny AT, Pope CG, Waddington H, Wallace V. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29, 38-45 (1926).
87. Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509-513 (1937).
88. Johnson AG, Gaines S, Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J. Exp. Med. 103, 225-246 (1956).
89. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59(4), 1317-1325 (1974).
90. Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell. Biol. 82(5), 497-505 (2004).
91. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 6, 141-228 (1995).
92. EMEA. Assessment report for Aflunov. Doc. ref.: EMEA/540171/2008 (2008).
93. Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43(9), 1135-1142 (2006).
94. Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80(10), 4962-4970 (2006).
95. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55(10), 1294-1298 (2006).
96. Saul A, Lawrence G, Allworth A et al. A human Phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23(23), 3076-3083 (2005). (Pubitemid 40462448)
97. Sheikh NA, Attard GS, van Rooijen N et al. Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation. Vaccine 21(25-26), 3775-3788 (2003).
98. Wu JY, Gardner BH, Kushner NN et al. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes. Cell Immunol. 154(1), 393-406 (1994).
99. Zhou F, Huang L. Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway. Immunomethods 4(3), 229-235 (1994). (Pubitemid 24318706)
100. Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186(1), 18-27 (1998). (Pubitemid 28285344)
101. + cytotoxic T lymphocyte responses. J. Immunol. 148(8), 2357-2362 (1992).
102. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344(6269), 873-875 (1990). (Pubitemid 20178886)
103. + cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Vaccine 13(17), 1669-1676 (1995). (Pubitemid 3011612)
104. Powers DC, Manning MC, Hanscome PJ, Pietrobon PJ. Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly. J. Infect. Dis. 172(4), 1103-1107 (1995).
105. White WI, Cassatt DR, Madsen J et al. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 13(12), 1111-1122 (1995).
106. Kozlovska TM, Cielens I, Dreilinna D et al. Recombinant RNA phage Q β capsid particles synthesized and self-assembled in Escherichia coli. Gene 137(1), 133-137 (1993). (Pubitemid 24053742)
107. Klovins J, Overbeek GP, van den Worm SH, Ackermann HW, van Duin J. Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages. J. Gen. Virol. 83(Pt 6), 1523-1533 (2002).
108. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo CJ, Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J. MoI. Biol. 380(1), 252-263 (2008).
109. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 38(1), 114-126(2008).
110. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 178(4), 2415-2420 (2007). (Pubitemid 46233441)
111. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs 7(9), 1475-1482 (1998).
112. + cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur. J. Immunol. 21(6), 1523-1527(1991).
113. Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75(1), 408-416 (2007).
114. Nguyen TV, Yuan L, Azevedo MS et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like partide-immunostimulating complex boosting vaccine regimen. Clin. Vaccine Immunol. 13(4), 475-485 (2006).
115. Morrow WJ, Yang YW, Sheikh NA. Immunobiology of the Tomatine adjuvant. Vaccine 22(19), 2380-2384 (2004).
116. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7(3), 179-190 (2007).
117. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not Toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol. 165(10), 5780-5787 (2000). (Pubitemid 30836191)
118. Baldridge JR, McGowan P, Evans JT et al. Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther 4(7), 1129-1138 (2004).
119. Krieg AM, Yi AK, Maison S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
120. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408(6813), 740-745 (2000). (Pubitemid 32015992)
121. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2(8), 675-680 (2001).
122. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA 95(26), 15553-15558 (1998).
123. Vollmer J, Weeratna R, Payette P et al. Characterization of three CpG oligodeoxynudeotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34(1), 251-262 (2004).
124. Aebig JA, Mullen GE, Dobrescu G et al. Formulation of vaccines containing CpG oligonucleotides and alum. J. Immunol. Methods 323(2), 139-146 (2007). (Pubitemid 46890965)
125. Hartmann G, Weeratna RD, Ballas ZK et al. Delineation of a CpG phosphorothioate oligodeoxynudeotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3), 1617-1624 (2000). (Pubitemid 30067282)
126. Mullen GE, Giersing BK, Jose-Popoola O et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynudeotide. Vaccine 24(14), 2497-2505 (2006).
127. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216 (2004).
128. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3(8), 849-854 (1997).
129. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157(5), 2116-2122(1996).
130. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188(12), 2335-2342 (1998).
131. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156(12), 4570-4575 (1996).
132. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell Immunol. 167(1), 72-78 (1996).
133. Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J. Immunol. 156(2), 558-564 (1996).
134. Odean MJ, Frane CM, Van derVieren M, Tomai MA, Johnson AG. Involvement of γ interferon in antibody enhancement by adjuvants. Infect. Immun. 58(2), 427-432 (1990).
135. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc. Natl Acad. Sci. USA 86(11), 4240-4243 (1989).
136. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263(5144), 235-237 (1994). (Pubitemid 24067932)
137. Bliss J, Van Cleave V, Murray K et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol. 156(3), 887-894 (1996). (Pubitemid 26048079)
138. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415 (1995).
139. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17(20-21), 2517-2527 (1999). (Pubitemid 29314444)
140. Jankovic D, Caspar P, Zweig M et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159(5), 2409-2417 (1997). (Pubitemid 127681034)
141. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007). (Pubitemid 47607848)
142. Verstraeten T, Descamps D, David MP et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26(51), 6630-6638 (2008).
143. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA 97(2), 811-816 (2000).
144. Klavinskis LS, Gao L, Barnfield C, Lehner T, Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine 15(8), 818-820 (1997).
145. Hartikka J, Bozoukova V, Ferrari M et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19(15-16), 1911-1923 (2001).
146. Lingnau K, Egyed A, Schellack C, Mattner F, Buschle M, Schmidt W. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20(29-30), 3498-3508 (2002). (Pubitemid 35248074)
147. O'Hagan DT, Singh M, Kazzaz J et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20(27-28), 3389-3398 (2002). (Pubitemid 35245822)
148. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51(1-3), 81-96 (2001).
149. Hinkula J, Devito C, Zuber B et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 24(21), 4494-4497 (2006). (Pubitemid 43776772)
150. Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28(3), 279-284 (1991).
151. Waters RV, Terrell TG, Jones GH. Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun. 51(3), 816-825 (1986).
152. Vogel FR. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30(Suppl. 3), S266-S270 (2000).
153. high regulatory T cells in acute dengue infection. J. Exp. Med. 204(5), 979-985 (2007).
154. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl Acad. Sci. USA 101(45), 16004-16009 (2004).
155. Ohashi PS, Oehen S, Buerki K et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65(2), 305-317 (1991). (Pubitemid 121006060)
156. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65(2), 319-331 (1991). (Pubitemid 121006061)
157. Moore ML, Peebles RS Jr. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol. Ther. 112(2), 405-424 (2006).
158. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89(4), 405-421 (1969).
159. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969).
160. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70(5), 2852-2860 (1996). (Pubitemid 26121897)
161. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC III, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68(8), 5321-5325 (1994). (Pubitemid 24226607)
162. Prince GA, Denamur F, Deschamps M et al. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19(15-16), 2048-2054 (2001). (Pubitemid 32178354)
163. Delgado MF, Coviello S, Monsalvo AC et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15(1), 34-41 (2009).
164. Buonaguro L, Tornesello ML, Tagliamonte M et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol. 80(18), 9134-9143 (2006). (Pubitemid 44362963)
165. Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501-10506 (2008).
166. Buonaguro L, Monaco A, Arico E et al. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics 9(Suppl. 2), S5 (2008).
167. Buonaguro L, Tornesello ML, Tagliamonte M et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol. 80, 9134-9143 (2006). •• Desdption of gene expression in peripheral blood mononuclear cells ex vivo exposed to enveloped PrGag-based HIV VLPs expressing gp120 on the surface. (Pubitemid 44362963)
168. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev. Vaccines 7(1), 7-10 (2008). (Pubitemid 351359053)
169. Bosch FX, Burchell AN, Schiffman M et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl. 10), K1-K16 (2008).
170. Munoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003). •• Classification of HPV types in high- and low-risk groups by oncogenic potential.
171. Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107(1), 18-27 (2006).
172. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757-1765 (2004). •• Phase II study report of the initial efficacy study for Cervarix™. (Pubitemid 39488060)
173. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
174. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent Ll virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(95SO), 2161-2170 (2007). •• Phase III interim report at 15 months showing vaccine efficacy against HPV-16 and -18-related cervical intraepithelial neoplasia (CIN) grade 2/3 and cross-protection for HPV-45 and -31 for Cervarix. (Pubitemid 46977438)
175. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95(11), 1459-1466(2006).
176. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007).
177. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007).
178. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006). (Pubitemid 44080367)
179. Pedersen C, Petaja T, Strauss G et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40(6), 564-571 (2007). (Pubitemid 46771257)
180. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6(5), 271-278 (2005).
181. Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25(26), 4931-4939 (2007).
182. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369(9576), 1861-1868 (2007). •• Meta-analysis of all Gardasil® data to show quadrivalent vaccine efficacy against HPV-16/18-related CIN2/3.
183. Paavonen J. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr. Med. Res. Opin. 24(6), 1623-1634 (2008).
184. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol. Oncol. 110(3 Suppl. 1), S1-S10 (2008). •• Phase II study report after 6.4 years of follow-up for Cervarix.
185. Hildesheim A, Herrero R, Wacholder S et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7), 743-753 (2007). •• Documents the lack of efficacy of HPV vaccination with Cervarix in women previously infected with HPV-16 and -18. (Pubitemid 47263157)
186. Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J. Infect. Dis. 196(10), 1438-1446 (2007). •• Study documents the lack of efficacy of HPV vaccination with Gardasil in women previously infected with HPV-16 and -18.
187. Descamps D, Hardt K, Spiessens B et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin. 5(5), 332-340 (2009). •• Pooled analysis of 11 clinical trials to demonstrate safety of AS04 adjuvant present in Cervarix.
188. De Carvalho N, Roteli-Martins C, Teixeira J et al. Immunogenicity and safety of HPV-16/18 AS04-adjuvanted vaccine up to 7.3y. Presented at: 25th International Papillomavirus Conference (IPV). Malmo, Sweden, 8-14 May 2009 (Abstract 29.15).
189. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 26(Suppl. 10), K62-K67 (2008). •• Review on currently pursued strategies for second-generation HPV vaccines.
190. Scotti N, Alagna F, Ferraiolo E et al. High-level expression of the HIV-1 Pr55(gag) polyprotein in transgenic tobacco chloroplasts. Planta 229(5), 1109-1122 (2009).
191. Alphs HH, Gambhira R, Karanam B et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl Acad. Sci. USA 105(15), 5850-5855 (2008).
192. Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 24(13), 2238-2247 (2006). (Pubitemid 43290406)
193. van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev. Vaccines 7(1), 1-5 (2008).
194. Bousarghin L, Touze A, Gaud G et al. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol. Cancer Ther. 8(2), 357-365 (2009).
195. Kosukegawa A, Arisaka F, Takayama M, Yajima H, Kaidow A, Handa H. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochim. Biophys. Acta 1290(1),37-45(1996).
196. Chang D, Fung CY, Ou WC et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J. Gen. Virol. 78(Pt 6), 1435-1439 (1997).
197. Fernandez-Arias A, Risco C, Martinez S, Albar JP, Rodriguez JF. Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. J. Gen. Virol. 79(Pt 5), 1047-1054 (1998).
198. Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol. 68(9), 5945-5952 (1994). (Pubitemid 24258612)
199. Noteborn MH, Verschueren CA, Koch G, van der Eb AJ. Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. J. Gen. Virol. 79(Pt 12), 3073-3077 (1998).
200. Nawagitgul P, Morozov I, Bolin SR, Harms PA, Sorden SD, Paul PS. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J. Gen. Virol. 81(Pt 9), 2281-2287 (2000).
201. Brown CS, Van Lent JW, Vlak JM, Spaan WJ. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J. Virol. 65(5), 2702-2706 (1991).
202. Christensen J, Alexandersen S, Bloch B, Aasted B, Uttenthal A. Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. J. Gen. Virol. 75(Pt 1), 149-155 (1994).
203. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66(11), 6527-6532 (1992).
204. Pletneva MA, Sosnovtsev SV, Sosnovtseva SA, Green KY. Characterization of a recombinant human calicivirus capsid protein expressed in mammalian cells. Virus Res. 55(2), 129-141 (1998).
205. Hale AD, Crawford SE, Ciarlet M et al. Expression and self-assembly of Grimsby virus: antigenic distinction from Norwalk and Mexico viruses. Clin. Diagn. Lab. Immunol. 6(1), 142-145 (1999).
206. Belliot G, Noel JS, Li JF et al. Characterization of capsid genes, expressed in the baculovirus system, of three new genetically distinct strains of 'Norwalk-like viruses'. J. Clin. Microbiol. 39(12), 4288-4295 (2001).
207. Li TC, Yamakawa Y, Suzuki K et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 71(10), 7207-7213 (1997). (Pubitemid 27391654)
208. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 307(5947), 178-180 (1984).
209. Kunke D, Broucek J, Kutinova L et al. Vaccinia virus recombinants co-expressing hepatitis B virus surface and core antigens. Virology 195(1), 132-139 (1993). (Pubitemid 23209991)
210. Rasmussen L, Battles JK, Ennis WH, Nagashima K, Gonda MA. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology 178(2), 435-451 (1990). (Pubitemid 20349881)
211. Morikawa S, Booth TF, Bishop DH. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors. Virohgy 183(1), 288-297 (1991).
212. Thomsen DR, Meyer AL, Post LE. Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. J. Gen. Virol. 73(Pt 7), 1819-1824(1992).
213. Johnson MC, Scobie HM, Vogt VM. PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J. Virol. 75(9), 4407-4412 (2001).
214. Kakker NK, Mikhailov MV, Nermut MV, Burny A, Roy P. Bovine leukemia virus Gag particle assembly in insect cells: formation of chimeric particles by domain-switched leukemia/lentivirus Gag polyprotein. Virology 265(2), 308-318 (1999). (Pubitemid 30022225)
215. Rafnar B, Tobin GJ, Nagashima K et al. Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells. Virus Res. 53(2), 107-120 (1998). (Pubitemid 28127848)
216. Nagy E, Huber P, Krell PJ, Derbyshire JB. Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV. J Gen. Virol. 72(Pt 3), 753-756 (1991).
217. Pink JR, Kieny MP. 4th Meeting on Novel Adjuvants Currently In/Close to Human Clinical Testing. World Health Organization - organisation Mondiale de la Sante Fondation Merieux, Annecy, France, 23-25 June 2003. Vaccine 22(17-18), 2097-2102 (2004).